


Vidac Pharma Announces Publication of New Peer-Reviewed Study Highlighting Breakthrough Anti-Cancer Mechanism of VDA1275

The article explores the potential of VDA1275 both as a standalone therapy and in synergistic combination with traditional chemotherapy

LONDON, UNITED KINGDOM, June 10, 2025 /EINPresswire.com/ -- <u>Vidac</u> <u>Pharma</u>, a clinical-stage biopharmaceutical company developing innovative cancer therapies, is pleased to announce the publication of a new peer-reviewed



scientific article that explores the potential of its proprietary compound VDA1275—both as a standalone therapy and in synergistic combination with traditional chemotherapy.

The article, published in "Journal of Nanomedicine& Biotherapeutic discovery" provides an in-

٢

This study marks an important milestone in our mission to develop therapies that overcome tumor resistance and enhance the effectiveness of existing treatments" *Dr. Max Herzberg* depth look at the mechanism of action of VDA1275, a promising new drug candidate for the treatment of solid tumors.

The study highlights VDA1275's triple mechanism of action:

• Reversal of the Warburg effect: VDA1275 disrupts excessive glycolysis in cancer cells, restoring normal cellular metabolism.

 Reactivation of apoptosis: By reopening the mitochondrial pore, VDA1275 restores programmed cell

death pathways that are often disabled in tumors.

• Modulation of the tumor microenvironment (TME): VDA1275 reduces lactate production, creating a more favorable microenvironment that enhances the efficacy of chemotherapeutic

agents and promotes a pro-immune response.

This breakthrough adds to Vidac Pharma's growing oncology pipeline. The company's lead drug candidate, Almavid[™] (a proprietary formulation of Tuvatexib (VDA1102)), is currently undergoing advanced development for subcutaneous administration across multiple cancer types.

VDA1275, designed for oral administration, complements Almavid[™] and has demonstrated highly synergistic activity when used in combination with classical chemotherapy agents, as detailed in this collaborative research with HCS scientists.

"We are excited to see the promising data on VDA1275's unique mechanism and its potential to improve outcomes for cancer patients," said Dr. Max Herberg, Active Chairman & CEO at Vidac Pharma. "This study marks an important milestone in our mission to develop therapies that overcome tumor resistance and enhance the effectiveness of existing treatments."

Vidac Pharma remains committed to advancing its innovative oncology programs and bringing new hope to patients worldwide.

Max Herzberg / Sandra Gamzon Vidac pharma Holding Plc +972 54-425-7381 email us here Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/820378753

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.